Exploring Analyst Estimates for Insulet (PODD) Q4 Earnings, Beyond Revenue and EPS

Core Viewpoint - Insulet (PODD) is expected to report a quarterly earnings per share (EPS) of $1.48, marking a 28.7% increase year-over-year, with revenues projected at $767.33 million, reflecting a 28.4% year-over-year growth [1]. Earnings Estimates - The consensus EPS estimate for the quarter has remained unchanged over the past 30 days, indicating that analysts have not revised their initial projections [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Revenue Projections - Analysts predict 'Revenue- Total Omnipod' to be $765.48 million, indicating a year-over-year increase of 30.7% [5]. - The 'Revenue- Drug Delivery' is estimated to reach $0.97 million, which represents a significant decline of 91.8% from the previous year [5]. - The consensus for 'Revenue- International Omnipod' is set at $209.64 million, showing a year-over-year increase of 47.6% [5]. - 'Revenue- U.S. Omnipod' is expected to be $555.84 million, reflecting a year-over-year growth of 25.3% [6]. Stock Performance - Over the past month, Insulet shares have decreased by 11.3%, while the Zacks S&P 500 composite has only declined by 0.3% [6]. - Insulet currently holds a Zacks Rank of 4 (Sell), suggesting it may underperform the overall market in the near future [6].